Competing risks of death in younger and older postmenopausal breast cancer patients

Table 3 Multivariate factor effects by type of death

Factor1	β(SE)2	95%CI2	P-value3
Breast cancer survival4
Treatment (Tamoxifen, Tamoxifen + Octreotide LAR)	0.0008(0.17)	[-0.33, 0.33]	1.00
Adjuvant chemotherapy (no, yes)	0.2553 (0.20)	[-0.14, 0.65]	0.20
Number of positive nodes
(0, Nx, 1-3, ≥ 4+)	-0.2524 (0.08)	[-0.41,-0.10]	0.002
Hormone receptor status (ER-PR-, unknown ER/PR, ER+ and/or PR+)	0.2821 (0.13)	[0.03,0.54]	0.03
Tumour size (T1, ≥ T2, unknown)	-0.6521 (0.18)	[-1.00,-0.30]	0.0003
Other Cause Survival
Treatment (Tamoxifen, Tamoxifen + Octreotide LAR)	0.1236 (0.18)	[-0.23, 0.48]	0.49
Adjuvant Chemotherapy (no, yes)	-0.0703 (0.23)	[-0.52, 0.38]	0.76
Number of positive nodes
(0, Nx, 1-3, ≥ 4+)	-0.0723 (0.08)	[-0.23, 0.08]	0.38
Hormone receptor status (ER-PR-, unknown ER/PR, ER+ and/or PR+)	-0.3852 (0.26)	[-0.89,0.12]	0.13
Age (years)	-0.0389 (0.01)	[-0.06,-0.02]	0.002
BMI (continuous)	-0.0395 (0.01)	[-0.06,-0.02]	0.01

¹Cause-specific survival model was built using ln(survival time) having linear function of β x (factor values). The model had forced inclusion of treatment and stratification factors (adjuvant chemotherapy, nodal status, and hormone receptor status) with step-wise forward inclusion of other baseline factors;

²β is effect of factor; SE is standard error; CI is confidence interval assuming β is approximately normally distributed;

³P-value is that for a Wald statistic;

⁴Higher values of continuous C-peptide were associated with worse BrCa (P = 0.08).